Future Science Group
supplementary figure 1.pdf (1022.45 kB)

Supplementary figure 1.pdf: A Phase I trial of talazoparib in patients with advanced hematologic malignancies

Download (1022.45 kB)
posted on 2021-10-23, 12:03 authored by Ajay K Gopal, Rakesh Popat, Ryan J Mattison, Tobias Menne, Adrian Bloor, Terry Gaymes, Asim Khwaja, Mark Juckett, Ying Chen, Matthew J Cotter, Ghulam J Mufti
Supplementary Figure 1. Dose linearity and proportionality in plasma following multiple doses of talazoparib.


This study was sponsored by Biomarin/Medivation, which was acquired by Pfizer Inc. in September 2016 (grant number not applicable).